Haisco(SZ:002653) Shang Hai Zheng Quan Bao·2025-08-23 00:04Core Viewpoint - The company has approved the use of its own funds to pay for part of the investment project costs, which will later be replaced with raised funds, ensuring compliance with regulations and maintaining operational efficiency [23][29][31]. Group 1: Company Overview - The company is named Haishike Pharmaceutical Group Co., Ltd. and is publicly traded with the stock code 002653 [10]. - The company held its fifth board meeting on August 22, 2025, where all directors attended and approved the half-year report [2][5]. Group 2: Financial Data - The company raised a total of RMB 800 million through a non-public stock issuance, with a net amount of RMB 790.87 million after deducting issuance costs [11][23]. - The company has established a special account for the management of raised funds, ensuring compliance with regulatory requirements [12][23]. Group 3: Fund Usage - The company plans to use surplus funds from previous projects for new initiatives, including RMB 16.42 million for working capital and RMB 53.02 million for clinical research projects [25]. - The company has not changed the implementation location or method for any investment projects during the reporting period [14]. Group 4: Fund Management - The company has implemented a cash management strategy for temporarily idle raised funds, generating a cash return of RMB 1.39 million during the reporting period [15]. - The company has established a process for replacing its own funds with raised funds within six months, ensuring that the funds are used effectively [27][28]. Group 5: Compliance and Oversight - The board of directors has ensured that the use of self-funds for project payments complies with relevant regulations and does not affect the project's implementation [29][31]. - The company has received no negative feedback from its sponsor regarding the fund management practices [31].